Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system

Study aims: The aim of the current study was to evaluate the efficacy and safety of stepwise circumferential and focal ablation using the HALO system for Barrett’s esophagus containing flat, high-grade dysplasia (HGD) or residual dysplasia after endoscopic resection for HGD or intramucosal cancer (IMC).

Methods: Visible abnormalities were removed with endoscopic resection prior to ablation. Persistence of dysplasia and absence of IMC were confirmed with biopsy after endoscopic resection. A balloon-based electrode was used for primary circumferential ablation and an endoscope-mounted electrode was used for secondary focal ablation.

Results: Twelve patients (nine men; median age 70 years) were treated (median Barrett’s length 7 cm). Visible abnormalities were removed by endoscopic resection in seven patients. The worst pathological grade of residual Barrett’s esophagus after resection and prior to ablation was low-grade dysplasia (LGD) (n = 1) and HGD (n = 11). Patients underwent a median of one circumferential and two focal ablation sessions. Complete remission of dysplasia was achieved in 12/12 patients (100 %). Complete endoscopic and histological removal of Barrett’s esophagus was achieved in 12/12 patients (100 %). There were no ablation-related stenoses, and no subsquamous Barrett’s esophagus was observed in 363 biopsies obtained from post-ablation neo-squamous mucosa. Protocolized cleaning of the ablation zone and electrode in between ablations resulted in superior regression of Barrett’s esophagus compared with previous studies. During a median follow-up of 14 months no recurrence of dysplasia or Barrett’s esophagus was observed.

Conclusions: Stepwise circumferential and focal ablation for Barrett’s esophagus with flat HGD or for Barrett’s with residual dysplasia after endoscopic resection for HGD/IMC is a safe and effective treatment modality. Its success rate and safety profile compare favorably with alternatives such as esophagectomy, widespread endoscopic resection or photodynamic therapy.

References

• 1 Sharma V K, Wang K K, Overholt B F. et al . Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients.  Gastrointest Endosc. 2007;  65 185-195
• 2 Gondrie J J, Pouw R E, Sondermeijer C MT. et al . Step-wise circumferential and focal ablation of Barrett’s esophagus with high-grade dysplasia: results of the first prospective series of 11 patients.  Endoscopy. 2008;  40 359-369
• 3 Ganz R A, Utley D S, Stern R A. et al . Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus.  Gastrointest Endosc. 2004;  60 1002-1010
• 4 Dunkin B J, Martinez J, Bejarano P A. et al . Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device.  Surg Endosc. 2006;  20 125-130
• 5 Sharma P, Dent J, Armstrong D. et al . The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria.  Gastroenterology. 2006;  131 1392-1399
• 6 Aiko T, Sasako M. The new Japanese Classification of Gastric Carcinoma: Points to be revised.  Gastric Cancer. 1998;  1 25-30
• 7 Peters F P, Kara M A, Curvers W L. et al . Multiband mucosectomy for endoscopic resection of Barrett’s esophagus: feasibility study with matched historical controls.  Eur J Gastroenterol Hepatol. 2007;  19 311-315
• 8 Bergman J J. Endoscopic treatment of high-grade intraepithelial neoplasia and early cancer in Barrett’s oesophagus.  Best Pract Res Clin Gastroenterol. 2005;  19 889-907
• 9 Peters F P, Brakenhoff K PM, Curvers W L. et al . Histological evaluation of resection specimens obtained at 293 endoscopic resections in Barrett’s esophagus.  Gastrointest Endosc. 2007;  Epub ahead of print 1-6
• 10 Ell C, May A, Pech O. et al . Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer).  Gastrointest Endosc. 2007;  65 3-10
• 11 Bergman J J. Endoscopic resection for treatment of mucosal Barrett’s cancer: time to swing the pendulum.  Gastrointest Endosc. 2007;  65 11-13
• 12 Peters F P, Kara M A, Rosmolen W D. et al . Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett’s esophagus.  Gastrointest Endosc. 2005;  61 506-514
• 13 May A, Gossner L, Pech O. et al . Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach.  Eur J Gastroenterol Hepatol. 2002;  14 1085-1091
• 14 Pech O, Gossner L, May A. et al . Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia.  Gastrointest Endosc. 2005;  62 24-30
• 15 Overholt B F, Lightdale C J, Wang K K. et al . Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial.  Gastrointest Endosc. 2005;  62 488-498
• 16 Prasad G A, Wang K K, Buttar N S. et al . Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett’s esophagus.  Gastroenterology. 2007;  132 1226-1233
• 17 Ackroyd R, Brown N J, Davis M F. et al . Photodynamic therapy for dysplastic Barrett’s oesophagus: a prospective, double blind, randomised, placebo controlled trial.  Gut. 2000;  47 612-617
• 18 Peters F, Kara M, Rosmolen W. et al . Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in barrett esophagus after endoscopic resection.  Endoscopy. 2005;  37 418-424
• 19 Dulai G S, Jensen D M, Cortina G. et al . Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett’s esophagus.  Gastrointest Endosc. 2005;  61 232-240
• 20 Ackroyd R, Tam W, Schoeman M. et al . Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett’s esophagus after antireflux surgery.  Gastrointest Endosc. 2004;  59 1-7
• 21 Overholt B F, Panjehpour M, Halberg D L. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results.  Gastrointest Endosc. 2003;  58 183-188
• 22 Hornick J L, Blount P L, Sanchez C A. et al . Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett’s esophagus.  Am J Surg Pathol. 2005;  29 372-380
• 23 Van Laethem J L, Peny M O, Salmon I. et al . Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett’s oesophagus.  Gut. 2000;  46 574-577
• 24 Hage M, Siersema P D, Vissers K J. et al . Genomic analysis of Barrett’s esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci.  Int J Cancer. 2006;  118 155-160
• 25 Krishnadath K K, Wang K K, Taniguchi K. et al . Persistent genetic abnormalities in Barrett’s esophagus after photodynamic therapy.  Gastroenterology. 2000;  119 624-630
• 26 Ragunath K, Krasner N, Raman V S. et al . Endoscopic ablation of dysplastic Barrett’s oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness.  Scand J Gastroenterol. 2005;  40 750-758